Debt-to-equity in % of Sigyn Therapeutics, Inc. from Q2 2016 to Q3 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Sigyn Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q2 2016 to Q3 2025.
Sigyn Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -103 %, a 5.64% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Sigyn Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	-103	+6.16	+5.64%	30 Sep 2025
Q2 2025	-105	+4.22	+3.86%	30 Jun 2025
Q1 2025	-107	+2.83	+2.58%	31 Mar 2025
Q4 2024	-108	+6	+5.26%	31 Dec 2024
Q3 2024	-109	+6.77	+5.84%	30 Sep 2024
Q2 2024	-109	+9.8	+8.24%	30 Jun 2024
Q1 2024	-110	+14.5	+11.6%	31 Mar 2024
Q4 2023	-114	+13.7	+10.7%	31 Dec 2023
Q3 2023	-116	+32.8	+22%	30 Sep 2023
Q2 2023	-119	+145	+55%	30 Jun 2023
Q1 2023	-124	-1.38K	-110%	31 Mar 2023
Q4 2022	-128	-507	-134%	31 Dec 2022
Q3 2022	-149	-399	-160%	30 Sep 2022
Q2 2022	-264	-851	-145%	30 Jun 2022
Q1 2022	1.25K	+2.13K		31 Mar 2022
Q4 2021	380	+1.99K		31 Dec 2021
Q3 2021	250	+1.49K		30 Sep 2021
Q2 2021	586	+862		30 Jun 2021
Q1 2021	-872	-709	-435%	31 Mar 2021
Q4 2020	-1.61K	-1.49K		31 Dec 2020
Q3 2020	-1.24K	-1.12K	-920%	30 Sep 2020
Q2 2020	-276	-144	-110%	30 Jun 2020
Q1 2020	-163	+74.2	+31.3%	31 Mar 2020
Q4 2019	-121^*	+163		31 Dec 2019
Q3 2019	-122	+251	+67.4%	30 Sep 2019
Q2 2019	-131			30 Jun 2019
Q1 2019	-237			31 Mar 2019
Q4 2018	-284			31 Dec 2018
Q3 2018	-373			30 Sep 2018
Q3 2016	-282			30 Sep 2016
Q2 2016	-428			30 Jun 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.